SCM
EPRS

Sterling Capital Management’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Sterling Capital Management’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-12,331
Closed -$33K – 1045
2016
Q1 		$33K Sell
12,331
-1,593
-11% -$4.47K ﹤0.01% 901
2015
Q4 		$43K Buy
+13,924
New +$62.8K ﹤0.01% 975

Other funds holding EPRS

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sterling Capital Management's EPRS Position: Q2 2016 in Review

Sterling Capital Management sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q2 2016, closing a stake of 12,331 shares — an estimated $33K sold.

Sterling Capital Management first reported a position in EPRS in Q4 2015 and held it in 2 quarters. The position peaked at $43K in Q4 2015. 32 funds tracked by Wall St. Rank hold EPRS as of Q2 2016.

  • Sterling Capital Management reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • Sterling Capital Management sold 12,331 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q2 2016, an estimated $33K.
  • Sterling Capital Management first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q4 2015 and held it in 2 quarters.
  • Sterling Capital Management's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $43K in Q4 2015.
  • 32 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q2 2016.

Based on Sterling Capital Management's 13F filing for Q2 2016, filed 19 Aug 2016.